CHASE CARDIOVASCULAR PATCH KIT

K020233 · Chase Medical, Inc. · DXZ · Mar 14, 2002 · Cardiovascular

Device Facts

• Record ID: K020233
• Device Name: CHASE CARDIOVASCULAR PATCH KIT
• Applicant: Chase Medical, Inc.
• Product Code: DXZ · Cardiovascular
• Decision Date: Mar 14, 2002
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 870.3470
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The CHASE Cardiovascular Patch Kit is indicated for cardiac and vascular patch grafting.

Device Story

The Chase Cardiovascular Patch Kit is a surgical device used for cardiac and vascular patch grafting. It is intended for use by surgeons in an operating room setting. The device provides a patch material used to repair or reconstruct cardiac or vascular tissues. By facilitating the repair of defects in the heart or blood vessels, the patch helps restore structural integrity and normal function of the cardiovascular system. The kit is provided for prescription use only.

Clinical Evidence

No clinical data provided; substantial equivalence determination based on regulatory review of the 510(k) submission.

Technological Characteristics

Intracardiac patch device classified under 21 CFR 870.3470, Product Code DXZ. Technical specifications and material composition are not detailed in the provided documentation.

Indications for Use

Indicated for patients requiring cardiac and vascular patch grafting procedures.

Regulatory Classification

Identification

An intracardiac patch or pledget made of polypropylene, polyethylene terephthalate, or polytetrafluoroethylene is a fabric device placed in the heart that is used to repair septal defects, for patch grafting, to repair tissue, and to buttress sutures.

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of an eagle or other bird with its wings spread.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

## MAR 1 4 2002

Mr. Dave Hernon Vice President of Regulatory Affairs Chase Medical, Inc. 1710 Firman Drive, Suite 100 Richardson, TX 75081

Re: K020233

Trade Name: Chase Cardiovascular Patch Kit Regulation Number: 21 CFR 870.3470 Regulation Name: Intracardiac Patch Regulatory Class: Class II (two) Product Code: DXZ Dated: January 18, 2002 Received: January 23, 2002

Dear Mr. Hernon:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

#### Page 2 - Mr. Dave Hernon

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Dak Mell

- Bram D. Zuckerman, M.D. Acting Director Division of Cardiovascular and Respiratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# CHASE MEDICAL INC.

# CARDIOVASCULAR PATCH KIT

## Intended Use:

The CHASE Cardiovascular Patch Kit is indicated for cardiac and vascular patch grafting.

Division of Cardiovascular & Respiratory Devices
510(k) Number KO26233

**Prescription Use**
(Per 21 CFR 801.109)